Purple Biotech Past Earnings Performance
Past criteria checks 0/6
Purple Biotech's earnings have been declining at an average annual rate of -13%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been declining at an average rate of 61.1% per year.
Key information
-13.0%
Earnings growth rate
32.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | -61.1% |
| Return on equity | -60.6% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Purple Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -19 | 4 | 17 |
| 31 Dec 23 | 0 | -20 | 5 | 17 |
| 30 Sep 23 | 0 | -21 | 6 | 17 |
| 30 Jun 23 | 0 | -21 | 6 | 15 |
| 31 Mar 23 | 0 | -19 | 6 | 14 |
| 31 Dec 22 | 0 | -22 | 6 | 16 |
| 30 Sep 22 | 0 | -20 | 6 | 15 |
| 30 Jun 22 | 0 | -19 | 6 | 13 |
| 31 Mar 22 | 0 | -19 | 6 | 13 |
| 31 Dec 21 | 0 | -18 | 6 | 12 |
| 30 Sep 21 | 0 | -13 | 7 | 11 |
| 30 Jun 21 | -1 | -11 | 7 | 11 |
| 31 Mar 21 | 1 | -21 | 7 | 11 |
| 31 Dec 20 | 0 | -29 | 6 | 7 |
| 30 Sep 20 | 1 | -30 | 5 | 6 |
| 30 Jun 20 | 1 | -31 | 4 | 4 |
| 31 Mar 20 | 1 | -18 | 5 | 3 |
| 31 Dec 19 | 0 | -5 | 4 | 2 |
| 30 Sep 19 | 1 | -4 | 4 | 3 |
| 30 Jun 19 | 1 | -3 | 3 | 4 |
| 31 Mar 19 | 1 | -4 | 4 | 5 |
| 31 Dec 18 | 1 | -5 | 4 | 5 |
| 30 Sep 18 | 1 | -8 | 5 | 5 |
| 30 Jun 18 | 1 | -11 | 6 | 5 |
| 31 Mar 18 | 1 | -12 | 6 | 5 |
| 31 Dec 17 | 0 | -12 | 6 | 5 |
| 30 Sep 17 | 0 | -14 | 5 | 5 |
| 30 Jun 17 | 0 | -15 | 4 | 5 |
| 31 Mar 17 | 0 | -14 | 4 | 4 |
| 31 Dec 16 | 0 | -12 | 3 | 4 |
| 30 Sep 16 | 0 | -9 | 3 | 4 |
| 30 Jun 16 | 0 | -6 | 2 | 4 |
| 31 Mar 16 | 0 | -5 | 2 | 3 |
| 31 Dec 15 | 0 | -4 | 2 | 3 |
| 30 Sep 15 | 0 | -4 | 1 | 2 |
| 30 Jun 15 | 0 | -4 | 1 | 2 |
| 31 Mar 15 | 0 | -5 | 1 | 3 |
| 31 Dec 14 | 0 | -5 | 1 | 3 |
| 30 Sep 14 | 0 | -5 | 1 | 3 |
| 30 Jun 14 | 0 | -6 | 1 | 2 |
| 31 Mar 14 | 0 | -4 | 1 | 1 |
| 31 Dec 13 | 0 | -3 | 1 | 0 |
Quality Earnings: 1YI is currently unprofitable.
Growing Profit Margin: 1YI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1YI is unprofitable, and losses have increased over the past 5 years at a rate of 13% per year.
Accelerating Growth: Unable to compare 1YI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1YI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).
Return on Equity
High ROE: 1YI has a negative Return on Equity (-60.64%), as it is currently unprofitable.